NCT06760702: An ongoing trial by Aurigene Discovery Technologies Limited
This trial is ongoing. It must report results 2 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06760702 |
|---|---|
| Title | A Phase II, Open-label, Randomized, Dose-ranging Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers (TEJAS-2) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 9, 2024 |
| Completion date | Feb. 1, 2026 |
| Required reporting date | Feb. 1, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 3, 2026 |
| Days late | None |